Science

Dec 29, 2024, 10:10

Neoadjuvant atezolizumab plus chemotherapy for resectable NSCLC

Journal for ImmunoTherapy of Cancer posted on X about recent paper by Brian S. Henick et al., titled “Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings“.

Authors: Brian S. Henick, Peter D. Koch, Justin F. Gainor, Mark M. Awad, Codruta Chiuzan, Stephanie Izard, Yohanna Georgis, Samyukta Mallick, Robert F. Garofano, Cheryl V. Wong, Anjali Saqi, Jessica Grindheim, Katja Schulze, Joshua R. Sonett, Naiyer A. Rizvi, Benjamin Izar, Alison M. Taylor, Catherine A. Shu

“New JITC article: Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.”

Alison M. Taylor Anjali Saqi Benjamin Izar Brian S Henick cancer Catherine A. Shu Cheryl V. Wong Codruta Chiuzan Jessica Grindheim Joshua R. Sonett Journal for ImmunoTherapy of Cancer Justin F. Gainor Katja Schulze Mark M. Awad Naiyer A. Rizvi NSCLC OncoDaily Oncology Peter D. Koch Robert F. Garofano Samyukta Mallick Stephanie Izard Yohanna Georgis

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action